针对Clostridioides difficile感染和胃肠道出血的积极监测药监:基于病例控制研究的分析框架
Ravy K Vajravelu1, Amy R Byerly2, Robert Feldman3
1Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
全药典协会研究 (PharmWAS) 框架有效地识别了Clostridioides difficile感染和胃肠道出血的药物风险. 这种方法通过验证已知的药物相关疾病来增强药监.
科学领域:
- 药物监督和药物流行病学
- 计算生物学和生物信息学
背景情况:
- 积极监测药监测旨在检测意外的药物效应.
- 全药典相关性研究 (PharmWAS) 框架是为了减少药物相关性研究中的错误阳性结果而开发的.
- 这项研究评估了PharmWAS框架的可传输性和通用性,使用现实世界的医疗索赔数据.
研究的目的:
- 评估PharmWAS框架能够复制已知的药物关联的能力.
- 确认该框架在识别与Clostridioides difficile感染 (CDI) 和胃肠道出血 (GIB) 的关联方面的实用性.
主要方法:
- 病例控制研究是使用非识别的美国健康计划索赔数据进行的.
- 患有CDI (2010-2015年) 或GIB (2010-2021年) 的个人根据年龄和性别与对照进行了匹配.
- 条件后勤回归,调整风险因素和高维性倾向得分,用于分析药物相关性.
主要成果:
- 对于CDI,抗生素如西普洛撒,塞夫特里亚和勒沃撒显示出强烈的关联.
- 对于GIB,抗血小板药物,抗凝血剂和NSAIDs,如蒂卡格勒罗,纳普罗森和里瓦罗克萨班强烈相关.
- 该分析包括55137例CDI病例和450,315例GIB病例,检查了数百种药物.
结论:
- 该PharmWAS框架证明了在不同的健康状况中普遍性和可传输性.
- PharmWAS有可能增强传统的药物监测系统,用于识别不良药物事件.
- 进一步验证可以将PharmWAS确立为检测意外药物影响的有价值工具.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
09:42Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
Published on: August 26, 2014
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
